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Abstract
Background: The use of Clinical Data Management Systems (CDMS) has become essential in clinical trials to
handle the increasing amount of data that must be collected and analyzed. With a CDMS trial data are captured at
investigator sites with “electronic Case Report Forms”. Although more and more of these electronic data
management systems are used in academic research centres an overview of CDMS products and of available data
management and quality management resources for academic clinical trials in Europe is missing.
Methods: The ECRIN (European Clinical Research Infrastructure Network) data management working group
conducted a two-part standardized survey on data management, software tools, and quality management for
clinical trials. The questionnaires were answered by nearly 80 centres/units (with an overall response rate of 47%
and 43%) from 12 European countries and EORTC.
Results: Our survey shows that about 90% of centres have a CDMS in routine use. Of these CDMS nearly 50% are
commercial systems; Open Source solutions don’t play a major role. In general, solutions used for clinical data
management are very heterogeneous: 20 different commercial CDMS products (7 Open Source solutions) in
addition to 17/18 proprietary systems are in use. The most widely employed CDMS products are MACRO™ and
Capture System™, followed by solutions that are used in at least 3 centres: eResearch Network™, CleanWeb™, GCP
Base™ and SAS™. Although quality management systems for data management are in place in most centres/units,
there exist some deficits in the area of system validation.
Conclusions: Because the considerable heterogeneity of data management software solutions may be a hindrance
to cooperation based on trial data exchange, standards like CDISC (Clinical Data Interchange Standard Consortium)
should be implemented more widely. In a heterogeneous environment the use of data standards can simplify data
exchange, increase the quality of data and prepare centres for new developments (e.g. the use of EHR for clinical
research). Because data management and the use of electronic data capture systems in clinical trials are
characterized by the impact of regulations and guidelines, ethical concerns are discussed. In this context quality
management becomes an important part of compliant data management. To address these issues ECRIN will
establish certified data centres to support electronic data management and associated compliance needs of clinical
trial centres in Europe.
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Clinical research has become impossible without the use
of Clinical Data Management Systems (CDMS) to han-
dle the increasing amount of data that must be col-
lected, processed and analysed for clinical trials. In
general, trial data are collected at investigator sites with
special forms, so-called “Case Report Forms (CRF)”,
queried, cleaned, stored and analysed with the CDMS.
To reduce the possibility of errors, a CDMS employs
means to verify the correctness and plausibility of
entered data. Another function of CDMS is to code data
or to generate reports. The collection of clinical data by
means of electronic forms is called Electronic Data Cap-
ture (EDC) or Remote Data Entry (RDE). The advan-
tages of using EDC/RDE together with the internet for
data management have been recognised early [1-3]. But
it did require a long and slow adoption phase in pharma
industry and research institutions for the employment of
EDC software for clinical trials. Now in nearly half of all
trials clinical data are captured electronically [4]. It is
generally accepted that EDC/RDE systems can improve
the quality of data and accelerate clinical trial conduct
[5-7]. Because of restrictions in available funding
resources and special requirements for disease specific
infrastructures, academic clinical research centres are
less likely to implement CDMS solutions that are widely
used in pharma industry (e.g. Oracle Clinical™)a n d
often employ smaller and more specialised solutions or
develop their own systems. Nonetheless, advanced web-
based EDC can be employed very successfully in the
academic area [8,9]. For example, with 1500 study inves-
tigators and about 22000 randomized patients, INVEST
[8] is one of the largest Internet trials based on a web-
enabled trial system developed by the University of Flor-
ida (USA) including online enrolment, daily patient sta-
tus reports, records of study visit activities, and calendar
and resource management.
The European Clinical Research Infrastructure Net-
work (ECRIN) [10] is an ongoing EU-FP7 funded project
to support international academic clinical trials. ECRIN
links national networks of clinical research centres (CRC)
and clinical trials units (CTU) of 12 national networks
and EORTC, and will provide integrated services to
investigators and sponsors in multinational studies. To
support its trials ECRIN will employ an IT framework,
using data management systems located in dedicated
ECRIN data centres. As a first step to establish these data
centres an overview over the use and the state of CDMS
solutions employed by research centres in ECRIN was
needed. Therefore, an ECRIN wide survey was carried
out to determine the types of CDMS in use, the resources
available to the data management units and aspects of
quality management and GCP compliance.
The results of our survey show: the kind of infrastruc-
ture which is available in centres, what CDMS solutions
are in routine use, the state of quality management
applied to data management (DM) and the degree of
experiences in conducting data management for interna-
tional clinical trials.
Methods
The ECRIN data management working group conducted a
comprehensive standardised survey on data management
(DM), software tools and data management procedures for
clinical trials with 33 questions. The survey consisted of
two parts: a first survey was performed in March/April
2007, which was complemented by a short updated survey
in December 2008/January 2009. The second time the
new ECRIN members Switzerland and Austria partici-
pated in the survey. The questionnaires were sent to 167
ECRIN centres/units (172 in second survey); the response
rates were 47%/43% (78 completed questionnaires of the
initial survey and 74 completed questionnaires of the
updated survey). For Denmark, France, Germany and Italy
at least 10 questionnaires were received in the first survey
and France, Germany and UK provided at least 10
responses in the second survey (Figure 1).
To conduct the survey we did not apply for a vote of
an ethics committee. Ethical approval for the survey was
not necessary because first, no patient data were col-
lected and second, the survey involved our partner insti-
tutions of ECRIN and was related only to data about
DM structures and processes in general and was not
connected to a specific clinical trial.
Results
Characteristics of the survey
The survey addressed ECRIN clinical research centres
and clinical trial units in 12 European countries (Figure
1). With response rates of 47% and 43% the question
arises if statements made in our report can be represen-
tative for all centres. One has to consider that not all
centres that received a questionnaire conduct their own
data management. Thus, many centres which didn’tu s e
an own CDMS might not have answered the survey at
all. Nevertheless, because most questions addressed the
percentage of answers in relation to centres with their
own DM the answers might still give valuable informa-
tion about the structure, resources, and software used at
these centres. In addition, the response rate of the sur-
vey differed considerably between individual countries.
In the first survey countries like Denmark, Germany,
Italy and Spain, where nearly all centres answered,
exhibited a high degree of representativeness. But in
countries like France (27%), Ireland (50%), Sweden
(11%) and the UK (47%) which showed only a low
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rather limited. In an appended question of the survey
members were asked about the representativeness of
their centre’s data management for their country. Even
in low response countries, the self-estimated representa-
tiveness was relatively high. For example, in the case of
U K5o f8( 1m i s s i n g ) ,F r a n c e 8 of 12 (6 missing), Ire-
l a n d2o f4 ,S w e d e n1o f2( 1d o n ’t know) centres
declared their DM to be typical and representative for
their country. Thus, although the response rate was
rather low, the results generated were still valuable. In
addition, the value of the answers is strengthened by the
fact that answers came from many centres and units
that were members of large national clinical research
networks (UKCRN, SweCRIN, CIRN, KKS etc.) and
therefore often belonged to the leading academic clinical
research institutions of their country.
Characteristics of ECRIN centres that conduct clinical trials
Our survey shows that in general, existing ECRIN
centres support all types of trials with a clear focus on
trials of phase II (73%) and phase III (85%). 50% of
centres also conduct epidemiological trials. A smaller
number, but at least one third of centres, carry out
phase I trials, surgery trials and medical device trials.
The size and the activities of the centres were
assessed by the number of ongoing trials and the
number of persons employed. Most centres (31%) sup-
port less than 10 ongoing trials and employ less than
10 persons (30%); 19% of centres support 10-19 trials.
There exist some large centres: 15% of centres sup-
port more than 50 trials and 14% of centres employ
more than 50 persons. Thus, ECRIN spans a wide
range of different sizes of centres/units with a focus
on smaller ones.
Figure 1 Participation in data management survey of ECRIN. Number of participating CTC/CRU of ECRIN partner countries in first survey
(N left) and in update survey (N right). Grey: ECRIN member countries.
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in ECRIN centres
The vast majority of centres/units conduct data manage-
ment (DM): 64 centres (82% first survey) and 66 centres
(89% second survey) (Table 1). In already 61 centres
(95% of centres with own DM in first survey) and 55
centres (83% of centres with own DM in second survey)
a CDMS is in routine use (Table 1). Different types of
CDMS (Table 2) are employed with the focus on com-
mercial products (48%/59%) and proprietary solutions
(38%/32%) (Table 2). The share of commercial products
seems to have increased during the time between both
surveys. Altogether 20 different commercial CDMS pro-
ducts, 7 different Open Source solutions and 17/18 pro-
prietary solutions were identified (Table 3). The fraction
of employed Open Source solutions stays relatively
small (10%/6%). 79% of the CDMS are own installations
of the centre; two centres report access to a CDMS in
another unit and two centres have outsourced their
entire DM. Thus, outsourcing to external DM centres
or other units of an organization/university is still mini-
mal. Of the commercial products the most widely used
ones are (first number of first survey, second number of
second survey) MACRO™ (14/17) and Capture Systems™
(2/9), followed by solutions that are employed in at least
3 centres: eResearch Network™ (3/3), CleanWeb™ (0/3),
GCP Base™ (3/0) and SAS™ (3/3) (Table 4). MACRO™ is
a solution that is especially strong with academic custo-
mers and is used for example at the Diabetes Trial Unit,
University of Oxford, National Blood Service (UK), Insti-
t u tG u s t a v eR o u s s y ,P a r i s ,I n s t i t u tC u r i e ,P a r i s ,U n i v e r -
sity of Vienna, several KKS in Germany, Netherlands
Cancer Institute. Capture System™ from Clinsight is
used in particular by many French investigators.
Of the different functionalities a CDMS offers the most
widely used ones in ECRIN data centres/units are: data
collection (94% of centres using CDMS routinely), query
management (89%) and reporting (74%) (Figure 2). Double
data entry, safety management and study management are
supported in approximately 50% of centres with CDMS in
routine use. Thus, the focus of the use of CDMS is in data
collection and data evaluation, clearly the core functional-
ities of many centres. About 69% of CDMS (first survey)
are using electronic CRFs that allow for data collection at
investigator sites (RDE). Online RDE is a major
prerequisite for the efficient conduct of multicentre trials,
because it allows for centralized data collection. Human
resources in ECRIN data centres dedicated to DM are pre-
dominantly small and often centres have to manage with
only 2-3 persons for their DM (Figure 3).
Table 1 Overview of data management
Feature survey 1 survey 2
N% * N% *
data management performed within centre/unit 64 82 66 89
CDMS system in routine use 61** 95 55 83
Status of data management and CDMS used in ECRIN centres/units. N =
number of centres, *% of centres that perform DM. ** includes 4 centres that
use a CDMS located in another unit or that have outsourced their CDMS.
Table 2 CDMS in use
Category of CDMS survey 1 survey 2
N%N%
commercial system 29 48 41 59
open source 6 10 4 6
prorietary 23 38 22 32
others 3 5 2 3
Different types of CDMS in use in ECRIN centres/units. Multiple choices were
possible. Total of 61 answers (survey 1), 69 answers (survey 2), % of centres
that perform DM.
Table 3 CDMS products in use
Survey 1 Survey 2
Commercial products
MACRO™ MACRO™
eResearch Network™ Capture System™
SAS™ eResearch Network™
Capture System™ CleanWeb™
ECTrial™ SAS™
ClinInfo™ e-MedSolution™
secuTrial™ CITMAS™
ClinTrial™ ClinInfo™
EpiData™* IBM Lotus Notes™
Oracle™
SAS PheedIT™
secuTrial™
MS Access™
InfoPath™
Teleform™
WebSpirt™
SINATRAS™
Number of different commercial products
91 7
Open Source product
GCP Base™ LAMO Suite™
PhOSCo™ OpenClinica™
PsyGrid™ PhOSCo™
EpiData™ SPAD™
Number of different Open Source products
44
Self-developed proprietary systems
17 different systems 18 different systems
Spectrum of different CDMS products employed in ECRIN centres/units.
Multiple choices were possible. Products are mentioned by centres using
CDMS routinely. *One questionnaire specified EpiData™ as commercial
solution.
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A considerable number of ECRIN centres/units employ
special software or use a unique concept for data man-
agement in clinical trials:
1. The Copenhagen Trial Unit is using a groupware
platform for clinical trial DM. The unit employs
Lotus Notes/Domino™ from IBM implemented to
meet FDA requirements.
2. CITMAS™ covers patient tracking, enrolment, ran-
domisation, data capture and reporting.
3. JAVA based CleanWEB™ by Telemedicine Tech-
nologies is an integrated solution with designer, con-
nector and data collection by web browser. It offers
different types of randomisation and on-line
monitoring.
4. ClinInfo™, formerly developed for the Clinical
Pharmacology Service at University Claude Bernard
Lyon, has already been used for international studies
of large populations with integrated language
options.
5. e-MedSolution™ by International System House
Ltd. Budapest is a health care information system
and is used by the Hungarian centres for clinical
trials.
6. ECTrial™ is a clinical data base software.
7. SINATRAS™ is the EDC system developed by
SAKK for the CTU in Bern (Switzerland).
8. Some centres are using data analysis software
(SAS™,S P A D ™ by Decisia) or database software (MS
Access™) for their DM processes.
9. TeleForm™ (Electric Paper) enables the collection
of data from different kinds of forms (paper, HTML,
PDF) and consists of modules to design forms, scan
forms, read, verify and export data.
10. SAS PheedIT™ is a web- and SAS-based solution
with modules for study set-up, data entry, report
generation, validation management and data export.
11. The data mining software SPAD™,as u i t ef o r
exploratory and predictive analysis, is also used as a
CDMS. SPAD™ consists of data editor, data manage-
ment, export and transformation functions.
12. One centre is using MS InfoPath™, a tool to cre-
ate XML-based forms. It can be used in connection
with Windows SharePoint™ Services.
Open Source solutions for clinical data management
are of special interest in the academic community. For
Table 4 Prevalence of CDMS products
CDMS products survey 1 survey 2
MACRO™ 14 17
eResearch Network™ 33
Capture System™ 29
CleanWeb™ 03
GCP Base™ 30
SAS™ 33
ECTrial™ 20
e-MedSolution™ 02
Ranking of the most widely employed CDMS solutions in ECRIN centres/units.
Number (N) of centres using the product. Total of 61 answers (survey 1) and
69 answers (survey 2), multiple choices were possible. Indicated is the number
of times a centre that uses CDMS routinely mentioned a product name for
clinical DM.
Figure 2 Extend of functionalities in CDMS.I m p l e m e n t e d
functionalities of CDMS used in ECRIN centres (% of centres using
CDMS with corresponding functionalities). DDE (double data entry)
is the double input of paper based source data into the electronic
CRF to avoid type errors.
Figure 3 Human resources available for data management.
Human resources in ECRIN data centres: number of persons
employed in DM (% centres performing DM).
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large trials of complex interventions in mental health
and has been further developed to be used for all sorts
of trials. The PsyGrid™ system has been renamed
openCDMS™ (since Sep. 2008) and the software is now
available under a free licence (LGPLv3). openCDMS™ is
used amongst others by the UK Mental Health Research
Network, the UK Diabetes Research Network and the
National Institute of Health Research (UK). The system
is actively developed and maintained by a team of devel-
opers at the University of Manchester (UK). The modu-
lar web service architecture of the system enables
interoperability and even includes online randomisation
with email and SMS notification and reporting for pro-
ject management. PhOSCo™ is in use for several years
and was mentioned in both surveys. It uses XML for
clinical data and metadata. GCP BASE™ is a web-based
tool for remote data capture for clinical trials developed
at the Mario Negri Institute for Pharmacological
Research in Italy. It is released as free software under
the General Public Licence. EpiData™ consists of differ-
ent modules: “Entry” can be used for simple or pro-
grammed data entry and data documentation and
“Analysis” performs basic statistical analysis, graphs, and
data management.
Quality management of data management in
ECRIN centres
In the area of GCP compliant clinical trials, a quality
system must complement clinical data management
operations, to protect patients and to ensure that the
collected data are correct. This quality system prescribes
for example independent audits to determine whether
DM activities are conducted correctly according to
study protocols, standard operating procedures (SOPs),
and GCP. A quality management system for data man-
agement is in place in 64 (91%) centres/units performing
DM (first survey); 50 centres/units (78%) have data
management SOPs available. Although quality is
ensured by nearly all centres/units, over half of the cen-
tres still need to conduct complete system validation of
their DM (Figure 4). Only about one third of centres
validated their DM according to GCP and only 2 centres
(3%) performing DM have conducted full system valida-
tion covering GCP, FDA (electronic documents) and
GAMP. On the other hand, independent, external audits
have been performed in already 26 centres (41%) with
DM (Figure 4).
64 centres (82%) declared themselves able to provide
infrastructure and human resources to support multina-
tional trials. Experience with DM in international trials
exists in 47 (60%) centres and 44 (56%) centres have
reported to possess a CDMS suited for multinational trials.
Discussion
ECRIN data centres
Our survey shows that a majority of ECRIN centres/
units is conducting DM and employs a CDMS. About
half the centres use a commercial CDMS. But the rea-
lisation of DM for efficient and GCP compliant interna-
tional clinical trials is still a challenging venture for
academic research centres. To simplify this undertaking
ECRIN will create dedicated and certified “ECRIN Data
Centres” to provide DM services for international trials.
For this purpose ECRIN will use resources already avail-
able in ECRIN centres, instead of building own solutions
or buying new applications. Therefore, our survey was
supposed to give an overview of DM resources and soft-
ware solutions available in ECRIN and help to create an
inventory. Many of the listed CDMS solutions have
already been in use for many trials and ECRIN members
have gathered experience using them. But it must be
considered, that solutions used in ECRIN might not be
optimal for the support of international trials, which
have to be GCP-compliant as well as multilingual.
Heterogeneity of clinical data management solutions
Our survey covers many large European countries and
some of the smaller ones (Figure 1). To our knowledge,
this is the first time that an overview is published on
CDMS tools, DM resources and quality management
procedures within such a large number of academic
clinical centres in Europe. In contrast, most surveys
published have been concerned only with the proportion
of electronic data capture in relation to paper based data
collection. Recently the number of clinical trials con-
ducted with electronic data capture has been increased
considerably. A survey showed that between 2008 and
2009 45% of respondents already conducted more than
50% of their trials using EDC [11]. A recent analysis of
clinical trials in Canada showed that the adoption of
EDC systems in clinical trials is higher than indicated in
the literature [12]: it was estimated that 41% of clinical
trials were using an EDC system. Though, trials funded
by academic institutions and government were less likely
to use an EDC system compared to those sponsored by
industry.
Clearly, electronic data capture has reached academic
clinical research centres. Our survey shows that the DM
situation in European clinical centres and the CDMS in
use are surprisingly heterogeneous. In fact, the number
of different solution seems to have increased between
2008 and 2009 (Table 3). Not only is no single CDMS
product in predominant use, but also different concepts
are used for DM (e.g. groupware systems, clinical infor-
mation systems, data analysis systems are used for study
data collection). A large part of clinical centres uses
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used by any other centre. Open Source CDMS may be
an alternative [13], but have not yet been introduced on
a large scale so far. Only about 10% of centres use an
Open Source solution including GCP BASE™, PhOSCo™,
openCDMS™ (PsyGrid™) and EpiData™. OpenClinica™ an
Open Source solution which has recently gained in
popularity is only used by a single centre. Nonetheless,
we know of several centres that have installed OpenCli-
nica™ in addition to their routine system for evaluation.
Although many different CDMS are in use, solutions
w h i c ha r er e p r e s e n t e ds t r o n g l yi np h a r m ai n d u s t r y( e .
g. Medidata™,P h a s e F o r w a r d ™, and Oracle Clinical™)
were not mentioned. On the other hand, our survey
covers many CDMS which have never been mentioned
in previous surveys or market analyses [14-16]. A rea-
son for this may be that many vendors of commercial
solutions seem to focus for the most part on clients in
pharma industry with their considerable financial
resources and offer features, like a product or active
s u b s t a n c el e v e l ,t h a ta r en o tu s e f u li na c a d e m i c
trials. In addition, commercial software may be disad-
vantageous for academic research mainly because of
high costs and because of risks regarding delivery and
future software maintenance. Furthermore, software
licences should not restrict the integration with other
systems and the upgrading of the IT infrastructure of
academic centres. A reason for the high degree of het-
erogeneity may be the necessity to use specific CDMS
solutions for disease specific networks (e.g. cancer,
paediatrics, and psychiatrics). For academic trials the
shortening of the time to market for a product cannot
be the main objective for using a CDMS. For academic
clinical trials it is data quality, better recruitment and
am o r ee f f i c i e n tt r i a lc o n d u c tt h a tc o u n t s .T h ep r i m e
importance of data quality for academic trials is illu-
s t r a t e db yt h ef a c t ,t h a td a t aa n a l y s i ss o f t w a r ea n d
even data mining solutions are used as CDMS (e.g.
SAS™, PheedIT™,S P A D ™). Because ECRIN data centres
will support European international clinical trials, the
considerable heterogeneity in their available DM
resources and employed solutions may turn out to be
a hindrance for international cooperation and trial data
exchange. This may indicate the necessity to further
the implementation of common data standards like
CDISC (Clinical Data Interchange Standard Consor-
tium) in ECRIN.
The use of CDMS in clinical trials are characterised by
the impact of regulations on DM (e.g. 21 CRF Part 11,
EU GMP Guideline Vol. 4, Annex 11 Computerized
Figure 4 Quality management of data management. Availability of CDMS which comply with guidelines and legal requirements: left: DM
which is compliant with GCP, GAMP and FDA requirements (internal system validation) and right: DM which has undergone independent
validation (external audit). SV: system validation, GAMP: Good Automated Manufacturing Practice, FDA: Food and Drug Administration (here: 21
CFR Part 11), (shown are % centres performing DM).
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ments). For clinical centres employing CDMS it
becomes necessary to implement best practices for CRF
design, query resolution, and study start-up in an EDC
environment, including user acceptance testing, system
validation, creation of a data management plan and
training of investigators in the use of the application.
These requirements may cause considerable pressure on
t h eD Mr e s o u r c e so fad a t ac e n t r e .T op r o v i d et h e
necessary quality ECRIN data centres have to accom-
plish best practices with rather limited resources.
Because the most important factors for the quality of
clinical trial conduct are good clinical project manage-
ment together with efficient clinical data management,
clinical trial operations depend increasingly on the qual-
ity of the IT infrastructure. To conduct international
clinical trials IT-based collaborative support can become
even more useful because it enables remote monitoring,
adverse event notification, and remote review of clinical
operations across international sites and various time
zones. But our survey shows that most centres are
focused only on the core functions of DM (data collec-
tion, query management, reporting). This limitation may
be necessary in light of the limited resources available in
ECRIN data centres, but there is also the necessity to
improve quality management by harmonisation. Stan-
dards with respect to DM should be promoted in all
national networks of clinical trial units and clinical
research centres and resources for common quality
management should be exchanged. Because of the het-
erogeneity in CDMS the support of data exchange stan-
dards (CDISC, HL7, IHE) becomes a necessity for
cooperation in international clinical trials. Therefore,
ECRIN centres should try to jointly use DM resources
and enforce the support of CDISC standards.
Although highly sophisticated, some web-based EDC
systems still seem to show impairments [17], notably
that systems are not robust enough to handle the
workload (e.g. slow web page refreshing rate), that
EDC systems support different versions of basic soft-
ware (e.g. internet browsers) and that CRF pages are
not displayed correctly (e.g. missing data field boxes).
In addition, EDC systems often may generate unneces-
sary queries. To avoid these problems, quality manage-
ment, best practices and training will be important
aspects of DM services of ECRIN data centres. Our
survey shows that human resources in many ECRIN
centres are often small and that some deficits in qual-
ity management exist, especially in the use of system
validated CDMS and the documented evidence for
data management audits. For this reason the ECRIN
working group will design and implement an indepen-
dent certification process for ECRIN centres to certify
centres that are qualified to conduct GCP compliant
international trials [18]. To receive a certificate evi-
d e n c ef o rc o m p r e h e n s i v eq u a l i t ym a n a g e m e n tw i l lb e
of utmost importance and available resources and
workload will be critical factors.
ECRIN centres should prepare themselves for new
developments in the area of clinical trial DM. Our sur-
v e ys h o w st h a tt oal a r g ed e g r e eo n l yb a s i cf u n c t i o n a l -
ities of CDMS are supported. But in future, interfaces
between clinics, medical practices, and laboratories, as
well as integration with site management, electronic
patient reported outcomes (ePRO) and data warehouses
will become necessary components. Especially, electronic
health records (EHR) will be used increasingly for data
collection in clinical trials; because the EHR does not
interrupt the investigator’sw o r k f l o wi naw a yt h eE D C
system does [19]. There will be the need to have CDMS
available in ECRIN data centres that will support such
EHR based data collection in the future. Therefore, in
the heterogeneous CDMS environment of ECRIN the
dedicated ECRIN data centres should encourage the use
of clinical research standards that allow for interoper-
ability with the EHR (e.g. CDISC healthcare link). This
m a ye v e nc o n t r i b u t et ot h es t r e a m l i n i n go fc l i n i c a l
research and therefore improve healthcare for patients.
For the implementation and the use of a CDMS an
ethical approval is in general not necessary. Nonetheless,
because clinical data management handles and processes
human data, it must comply with high ethical standards.
The ethical aspects are covered by the need for GCP
compliance of any CDMS that is used in a clinical trial.
GCP is a standard for design, conduct, performance,
monitoring, auditing, recording, analyses, and reporting
of clinical trials. Implementation of GCP not only pro-
vides assurance that trial data are credible and accurate,
b u ta l s ot h a tt h er i g h t s ,i n t e g r i t y ,a n dc o n f i d e n t i a l i t yo f
trial subjects are protected [20]. In topic 5.5.3 GCP regu-
lates details of using electronic trial data and electronic
trial data systems (e.g. audit trail, SOPs, security system,
backup). In addition, European Directive 2001/20/EC
[21] regulates certain ethical aspects of clinical data man-
agement by requiring the existence of safeguards for the
rights of trial subjects to privacy and to the protection of
their personal data. GCP compliance and data security is
guaranteed by a process called “system validation” in
which requirements and specifications of CDMS are eval-
uated. Complete system validation documentation must
be produced in case a centre is audited by authorities. In
this way, an extensive certification process may support
ethical considerations when using a CDMS, ensuing that
patient data are collected correctly and used adequately.
Conclusions
Electronic data capture with professional solutions is
already used to a large degree in academic clinical
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Page 8 of 10research in Europe. Therefore, ECRIN data centres are
well prepared to support international trials. Electronic
data capture, data transfer, and web-based systems all
can facilitate DM of international clinical trials. ECRIN
centres support their DM with a multitude of different
CDMS, though the number of trials and human
resources are rather small. In addition to dedicated EDC/
RDE-systems, several data analysis and data mining solu-
tions are used for DM, illustrating the prime importance
of data quality for academic trials. Because ECRIN data
centres will support European international clinical trials,
the considerable heterogeneity of CDMS may be a hin-
drance for international cooperation and trial data
exchange. This potential problem indicates the necessity
to implement in national clinical networks common data
standards like CDISC. In a heterogeneous environment
the use of data standards can simplify data exchange as
well as increase the quality of data. Data management
and the use of EDC systems in clinical trials are charac-
terized by the impact of regulations and guidelines.
Thereby quality management becomes an important part
of compliant DM. To address these issues ECRIN will
establish certified data centres to support GCP compliant
electronic DM. Because we identified as most important
task for clinical research centres to improve their quality
management system, especially the validation and GCP
compliance of DM, future tasks of ECRIN should be the
harmonisation of DM resources for common quality
management procedures and self-audits between centres.
Based on the results of our survey the ECRIN Working
Group on Data Management will develop a certification
process for ECRIN data centres, promote the use of
CDISC standards in DM, encourage the harmonisation
of quality management and system validation, and sup-
port international cooperation of clinical DM.
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